Performance Measures in the Management of Chronic Obstructive Pulmonary Disease in Primary Care - A Retrospective Analysis

Kaufmann, Carla; Markun, Stefan; Hasler, Susann; Dalla Lana, Kaba; Rosemann, Thomas; Senn, Oliver; Steurer-Stey, Claudia

DOI: https://doi.org/10.1024/1661-8157/a002101

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-112544

Originally published at:
Kaufmann, Carla; Markun, Stefan; Hasler, Susann; Dalla Lana, Kaba; Rosemann, Thomas; Senn, Oliver; Steurer-Stey, Claudia (2015). Performance Measures in the Management of Chronic Obstructive Pulmonary Disease in Primary Care - A Retrospective Analysis. Praxis, 104(17):897-907.
DOI: https://doi.org/10.1024/1661-8157/a002101
Performance measures in the management of chronic obstructive pulmonary disease in primary care – A retrospective analysis

Carla Kaufmann¹, MD; Stefan Markun¹, MD; Susann Hasler¹, MD; Kaba Dalla Lana¹, PRT; Thomas Rosemann¹, MD, PhD; Oliver Senn¹, MD; Claudia Steurer-Stey¹*, MD

¹ Institute of Primary Care, University of Zurich

email addresses
Corresponding author *

Claudia Steurer-Stey* claudia.stey@usz.ch
Carla Kaufmann: ca.kaufmann@bluemail.ch
Stefan Markun: stefan.markun@usz.ch
Susann Hasler: susann.hasler@usz.ch
Kaba Dalla Lana: kaba.dallalana@usz.ch
Thomas Rosemann: thomas.rosemann@usz.ch
Oliver Senn: oliver.senn@usz.ch

Institute of Primary Care, University of Zurich
Pestalozzistrasse 24
8091 Zurich
Switzerland
Phone: +41 44 255 26 62
Fax: +41 44 255 90 97

Running title: COPD and performance measures

Key words: Performance, measures, COPD, quality, primary care, retrospective
Introduction
The prevalence of chronic obstructive pulmonary disease (COPD) in Switzerland is approximately 10%, comparable to other European countries(1, 2). COPD is associated with high morbidity, increased mortality and enormous economic costs(1, 4). COPD has therefore became a focus of the “QualiCCare” project, initiated by the Swiss Federal Department of Home Affairs (FDHA) in 2011 with the aim to improve quality in chronic disease care on a national level. The driving force behind “QualiCCare” was the mounting evidence that patients with chronic health conditions do not receive recommended care despite existing clinical practice guidelines(5). This is a problem in particular for patients with COPD, who receive recommended treatment only during 50% of encounters with providers(6-8).
Studies from various countries have shown that successful COPD care with improved quality of life and reduced use of health care resources is based on appropriate pharmacological treatment, planned regular visits, patient education, adequate exacerbation management and collaborative, integrated disease management(9, 10, 11). Guidelines address management of stable COPD as well as exacerbations and give recommendations for evidence based care (5, 12). However, variations in treatment and non-adherence to recommendations have a negative impact on the quality of care (8, 13-15). The Institute of Medicine (IOM) quality report emphasizes the need for better assessment of care quality by measuring performance (16).
Primary care is pivotal in this respect (17-20) as providers can transfer recommendations and implement them into daily practice, prompting quality improvements in care delivery (16, 21). Therefore, the aim of the present study was to investigate the documentation of COPD PMs in primary care practices of the Canton Zurich in Switzerland, based on guideline recommendations(5, 12).

Methods
The study was part of the improving CARe in Obstructive Lung disease (CAROL) project. CAROL is a cluster-randomized controlled trial that aims to assess whether GP and primary care team participation in the COPD quality improvement intervention (“QualiCCare”) improves adherence to recommended care elements and processes and which evaluates the impact on COPD care. A detailed research protocol has been published elsewhere(22). The CAROL study (ClinicalTrials.gov: NCT01921556) was approved by the ethics committee of the Kanton Zurich (Ref. KEK-ZH_Nr, 2013-0189). Protection of privacy of both patients and the participating practices was ensured.
For this study a multi-site retrospective design was chosen analyzing the medical records of 14 different primary care practices in the canton of Zurich, with a focus on the two major regions “Winterthur” and “Zurich”, which care for both urban and rural populations.
Setting and participating practices

The participating practices were recruited from 30 practices (single and group practices) in the canton of Zurich who agreed to participate in the CAROL project. Five practices were located in the area of Winterthur. Winterthur is the second largest city in the canton with about 105’000 inhabitants. Zurich is the largest city with around 390’000 inhabitants. Its agglomeration is home to around 1.19 million people.

Nine practices were from the area of Zurich. One of the Zurich practices runs the validated “Living well with COPD” (LWWCOPD) program(9) since 2010. The LWWCOPD program is based on the Chronic Care Model(23) and can be applied to a variety of chronic illnesses and health care settings (24). Key elements of the LWWCOPD program are a practice team with defined roles, evidence-based practice incorporating guideline recommendations, patient education and self-management support as well as regular follow up and coordination of care(25).

Patient enrolment

Each participating GP reported patients with physician diagnosed COPD and regular outpatient visits in 2012. The selection criteria required that patients had a physician diagnosed COPD and had seen the GP at least three times in 2012, regardless of the reason for the consultation. Patients were excluded if they died before the end of 2012.

Data collection and analysis

Data collection comprised a 12-month retrospective medical chart review. Demographic and clinical characteristics were assessed.

We analyzed the documentation of COPD performance status by searching the medical notes for the following relevant measures. 1. Assessment of smoking status with smoking cessation advice and smoking cessation intervention; 2. Influenza vaccination; 3. Assessment and advice for physical activity; 4. Appropriate pharmacological treatment; 5. Instruction of correct inhalation technique; 6. Information about disease; 7. Instruction in exacerbation management and availability of a written action plan; 8. Advice or referral to pulmonary rehabilitation and 9. Proactive and integrated services indicating collaboration and networking with specialists, secondary and hospital tertiary care services as well as with other health care deliverers and community resources.

An independent and trained research assistant reviewed each patients medical records using a carefully developed checklist including the above specified performance measures (PM). Several data sources were studied, e.g. entries in the medical records, referral letters and invoice coding to ensure comprehensive data collection.
In order to assess the severity of COPD spirometry results from the time of diagnosis and follow-up measurements from 2012 were included in the data analysis. The majority (91/115) of the medical records were computer based, 24 were paper based.

**Outcome measures**

For each patient the number of documented performance indicators was calculated. A composite score was established and noted. A Score of 1: denoted the documentation of 0-2 PMs, a Score of 2 the documentation of 3-5 PMs, a Score of 3: the documentation of 6-8 PMs and a Score of 4: the documentation of all nine PMs.

These results were compared to the practice running the validated LWWCOPD program (practice B).

**Statistical analysis**

Patient characteristics and documented PMs are presented as means (range) and percentages for the total population and stratified according to the regions Zurich and Winterthur as well as the practice running the COPD program (practice B). Group comparisons of patient characteristics and PMs were performed by unpaired t-tests and chi-squared statistics as appropriate. Fisher exact test was used for small sample sizes (n<5).

**Results**

**Practices characteristics**

Data from 14 primary care practices (7 single, 7 group practices) were evaluated. Five of the practices were located in the region of “Winterthur” and nine in the “Zurich” region. Data from 115 patients (37 in Winterthur, 78 in Zurich) were available; the majority of the patient data were collected in group practices (83%) and from computer based (79%) medical records (table 1). The group practice in Zurich running the “Living well with LWWCOPD program” (practice B) contributed 20 computer based medical records to this study (table 1).

**Patient characteristics**

Data from 115 patients (57% male) with a mean age of 68 years (range 44-93) were analyzed (table 2). Most baseline characteristics of the patients showed no significant difference between the practices without a COPD program (Total-B) and the practice in Zurich with the COPD program (B). Patients from practice B were more likely to be active smokers, had received a diagnosis of COPD more recently and were subjected to significantly more spirometries in 2012.

In general, no big difference in patient characteristics existed between the COPD patients from the rural (Winterthur) and the urban (Zurich) population in our study. COPD patients from Winterthur had been diagnosed with COPD for a significantly shorter amount of time.
than those in Zurich (table 2). The burden of comorbidities was high with documentation of one or more comorbidities in 73% of patients. The most frequently documented comorbidities were hypertension (57%), followed by coronary heart disease (28%), depression (23%), diabetes (15%) and heart failure (9%). However, heart failure and diabetes were not documented in the twenty patients from practice B.

Spirometric confirmation of COPD was documented in 83%, either at the time of diagnosis or during follow up in 2012. The year of COPD diagnosis was documented in 94 of the 115 patients (82%) and ranged between 1997 and 2012; on average COPD diagnosis was established 5.28 years before the current data collection.

At the time of diagnosis, GOLD classification (12) was documented in 80 patients (70%). Of these 11% were classified as GOLD I, 64% as GOLD II, 21% as GOLD III and 4% as GOLD IV. GOLD classification in 2012 was documented in 87 of the 115 patients (76%) with 8% of COPD patients classified as GOLD I, 51% as GOLD II, 23% as GOLD III and 9% as GOLD IV.

Documentation of at least one of the main clinical symptoms of COPD (cough, sputum, and/or dyspnea) was found in 83% of the medical records. Dyspnea was the most frequently documented symptom in 68%, followed by cough in 54% and sputum production in 35% of patients.

In half (53%) of the patient records exacerbations could be tracked with an average of 1.4 exacerbations/year and ≥2 exacerbations within 12 months in 16% of patients. On average 1.24 hospitalizations per year because of COPD were necessary (table 2).

**Documentation of performance measures**

Table 3 and figure 1 show the documentation of non-pharmacological PMs.

**Smoking status and smoking cessation counseling:**

In total smoking status was documented in 95% of the patients. Fifty patients (46%) were current smokers. Pack years (py) were documented in 77% with an average of 56 py (range: 22-150 pack years). In 74% of the current smokers smoking cessation advice was given and a stop smoking program initiated in 52%. 70% of the current smokers were documented as being motivated to cease smoking, 34% were not.

*Practices without a COPD program (Total–B =A) vs. the practice with LWWCOPD program (B)*

The percentage of documented smoking cessation advice offered in active smokers was 65% in practices A, and 100% in practice B. A smoking cessation program was initiated in 38% of the smokers in practices A and in 92% of smokers in practice B, a significantly higher percentage (p<0.01).

**Influenza vaccination:**
Overall, half of the patients received an influenza vaccination/recommendation in 2012 without any statistical difference between the regions or between A (49%) and B (45%).

**Physical activity and pulmonary rehabilitation:**

In 60% of all patient records assessment of physical activity and in 53% motivation and advice for physical activity was detailed.

**Practices without COPD program (A) vs. practice with LWWCOPD program (B)**

In practices A assessment of physical activity was documented in 52% of patients compared to 95% of patients in B. All patients in practice B were given advice regarding pulmonary rehabilitation compared to eleven (12%) in A. In 85% of patients in practice B a referral to a pulmonary rehabilitation program was traceable compared to 12% of patients in the A practices. These differences were highly significant (p<0.01).

**Information about COPD, information about therapy and instruction in correct inhalation technique:**

These three quality indicators were documented in 45% to 48% of patients in practices A compared to 95% in practice B (the practice running the LWWCOPD program), denoting a significant difference (p<0.01).

**Exacerbation management and written action plan:**

Instructions regarding exacerbation management were traced in only 24% of patients records and an action plan recorded in only 16% of patients.

**Practices without COPD program (A) vs. practice with LWWCOPD program (B)**

Analysis of patients charts from A showed scant documentation of instructions regarding exacerbation management (8%) or the existence of an action plan (2%), with no regional difference between Zurich and Winterthur. Instructions for exacerbation management were documented in all patient notes from practice B and 80% additionally had a clear action plan recorded (p<0.01).

**Proactive follow up and integrated services for patient care:**

For 60% of all COPD patients integrated care was documented. Contact with pneumologists was registered in 57%, with hospitals in 39%, physiotherapists in 32% and community support services in 15%. In about half of all medical records, a proactive follow up of COPD patients was documented.

**Practices without COPD program (A) vs. practice with LWWCOPD program (B)**

In practices A integrated care was documented in 53% compared to 95% of patients in practice B (p<0.01). Collaboration with a specialist was documented in 40% of COPD
patients from A compared to 95% of patients from B. Proactive care and regular follow up was significantly more frequent in B (95%) compared to A (42%) (p<0.01).

**Pharmacological treatment:**
Table 4 summarizes the COPD treatment regimes prescribed. The mean number of documented COPD medications was 2.09 (range: 0-6 drugs) without any significant difference between settings A and B or between the regions of Zurich and Winterthur. 80 of 115 patients (70%) were treated with inhaled corticosteroids (ICS), 70 of 80 patients (61%) in combination with a long-acting beta2-agonist (LABA). With respect to the disease severity recorded (32% GOLD III or GOLD IV documented in 2012) and the frequency of exacerbations (16%) this reflects overtreatment. Patients with severe COPD and patients with frequent exacerbations received adequate treatment with ICS (86% and 81% respectively).

Eighty-one out of 115 (70%) patients were prescribed a long-acting antimuscarine antagonist (LAMA). Long-acting beta2-agonist (LABA) treatment was documented in 22%. Short acting beta2-agonists (SABA) were prescribed in 36% of the COPD patients, whereas none of the patients inhaled a short acting antimuscarine antagonist (SAM). Only 6 out of 115 patients (5%) were prescribed a combination of a short-acting beta2-agonist and a short-acting antimuscarine antagonist (SABA/SAMA). In Winterthur significantly fewer patients were given an ICS/LABA combination therapy (43%) compared to the Zurich practices. This was true both for those practices with and those without a COPD program (70% versus 69% respectively). In Winterthur significantly more patients were prescribed LAMA (84%), compared to the Zurich practices without the LWWCOPD program (59%). LAMA treatment was prescribed to 80% of patients in the practice implementing the LWWCOPD program. Treatment with LABA was documented in 32% of patients in Winterthur, and in 16% and 20% of the patients in the Zurich practices with and without the LWWCOPD program, showing no statistical difference (table 4).

**Composite score of documented performance measures:**
Overall all practices had low scores of 1 or 2 (in 60% of patients). A score of 1 (0-2 PMs documented) was found in 23%, a score of 2 (3-5 PMs) in 37% of patients. A score of 3 (6-8 PMs) could be established in 34% and the maximum score of 4 (with all nine PMs documented) in only 7% of the 115 medical records.

Comparison with B showed that significantly higher scores of 3-4 in 95% of patients were achieved compared to 29% in A.

**Discussion**

*Main findings*
This is the first evaluation of the documentation of COPD PMs in a primary care setting in Switzerland. Our data demonstrate a documentation gap in relation to recommended care and a wide variation between practices regarding documentation of COPD PMs. A significantly better documentation of COPD PMs was achieved with the implementation of a validated COPD program(26).

**Strength and limitations**

COPD represents an important condition in which improvement of care would in all likelihood have a high impact. A strength of our study was that the assessed measures were validated to demonstrate effects on clinically important patient outcomes. We did not rely on questionnaires sent to the GPs, but had patient records and data gathering systems systematically reviewed by an independent research assistant, thus ensuring comprehensive data collection.

Limitations of this study include the low sample size, documentation bias and generalisability of the results. The participation of practices and GPs that were part of the CAROL study, a prospective RCT, represent a selected and probably more motivated GP population. However, the latter would likely have biased the data toward an underestimation of the documentation gap. Small samples are more prone to the play of chance which means that the significant effects which are observed in this study may be skewed. In the practice implementing a COPD program a chest physician and a respiratory physiotherapist were part of the team and oversaw the LWWCOPD program. Referrals and coordination of care were therefore more easily accomplished. This redesign of care using an inhouse care team approach is not common in Swiss primary care. In addition, the quality of documentation was assessed in the canton of Zurich and cannot be generalized to Switzerland as a whole or other countries and health care systems.

Finally, yet importantly, missing documentation is not synonymous with poor performance. Some PMs may have been implemented but not documented by the GPs. It is also likely that in patients referred to specialists the PMs were documented but not explicitly mentioned in reports sent to the GPs. It is difficult to conclude from our data how wide the gap between current and ideal COPD practice is and how this gap varies across different organizations.

**Interpretation of findings in relation to previously published work**

Two thirds of patients in our study received smoking cessation advice, but only around half received recommendations regarding influenza vaccination.

Smoking cessation is the only intervention that slows the rate of lung function decline and improves survival in COPD patients(27, 28). The documented counselling rate in the present study is much better than the 50% reported from former Swiss primary care data and is more in line with international benchmarks(8, 13).
Influenza vaccination prevents acute exacerbations of COPD and reduces the rate of hospitalization by about 40%-50% (29). The low documented influenza vaccination percentage (only half of the COPD patients) therefore reflects a substantial deficit with negative implications for patients and the health care system. This could be changed by implementing reminder and recall interventions, as shown in data from other countries (30). Our data also indicate that only a minority of COPD patients in primary care are offered pulmonary rehabilitation advice or a referral for pulmonary rehabilitation, in line with data from other countries (13). The remarkably low documentation of self-management support and exacerbation-management or instruction with a written action plan is striking. Pulmonary rehabilitation and self-management education are effective ways of lessening the impact of COPD burden on patients and the health system by preventing exacerbations and hospital admissions as well as readmissions (9, 31). In half of the patient records documentation of exacerbations was found. The percentage of frequent exacerbations (16% of patients) and an average of 1.24 hospitalizations per year because of COPD exacerbations suggest that the awareness for these as the main drivers of morbidity and cost has to be increased and that rehabilitation and self-management education need to be proclaimed as effective preventive actions, in analogy to programs established for heart disease (32). A recently published report by Australian GPs identified an awareness barrier, insufficient knowledge of how to refer for pulmonary rehabilitation, anticipated access difficulties for patients and cost benefit issues as major problems (33).

Spirometric confirmation of COPD with a remarkably high documentation of GOLD grading according to guidelines (5) revealed that the majority of evaluated COPD patients have mild to moderate COPD. A lasting hot topic in COPD management is pharmacological overtreatment with ICS in patients with mild to moderate disease, as confirmed in our study (5, 12). While overtreatment with ICS was common, undertreatment in those with severe disease or frequent exacerbations was less frequent.

With respect to effective treatment a correct inhalation technique is of central importance and depends on the correct use of the inhalation device. Instruction of inhalation technique was performed significantly more often in the practice with the COPD program, where almost all of the patients were trained compared to less than half of the patients from the other practices. Last but not least a change from reactive to more proactive and integrative care is necessary to achieve better outcomes in COPD (10, 18, 34). A significantly higher percentage of proactive follow up and integrated care in the practice implementing the COPD program was found, which can be explained by the integration of a chest physician, respiratory physiotherapist and a trained practice assistant into the team, facilitating referrals, information transfer and care coordination.
Taking together all our data, we found that one third of the patients from general health care practices received documented high quality care compared to 95% of the patients enrolled in the LWWCOPD program. These rather impressive differences warrant deeper reflection and discussion.

The LWWCOPD program(9) is based on the Chronic Care Model (CCM)(23). The CCM identifies the essential elements of a health care system that encourages high-quality chronic disease care. These elements are part of a health system that redesigns care according to a care team approach. It uses clinical information systems, supports self-management, and facilitates decision support. The focus lies on forming productive interactions between informed patients who take an active part in their care and providers with resources and expertise. The practice with the COPD program used some of these elements to improve chronic care delivery. A COPD care team (lungs physician, respiratory physiotherapist and trained practice assistants) dedicated to guideline based, proactive, coordinated care, supported self-management, offered regular follow up calls to patients and ensured an information transfer between the health care deliverers and the patient.

**Implications for practice, policy and research**

21st century practices should incorporate evidence based processes of care. It is not enough to create guidelines but recommendations have to be incorporated into daily practice. PMs are a postulated tool to help improve health-care quality(21). In the United Kingdom, the National Institute for Health and Clinical Excellence (NICE) guideline implementation strategies use financial and regulatory incentives, including pay-for-performance(35). However, concerns in linking financial incentives to performance exist. It is argued that performance measures are poor predictors of quality and that rewarding quality improvement actions could make more sense than spending resources on measures(36). PMs alone will not improve care unless the results of those measures are linked to efforts to diagnose and eliminate core causes of poor quality and point the way to integrating and coordinating care(37). Some of the most established causes for poor quality are a lack of resources to transform practices and implement quality improving health care delivery concepts like the CCM and the patient centered medical home (PCMH)(23, 34). A central cornerstone for better quality will be value-based reimbursement, rewarding those who contribute to high-quality, cost-effective care across the continuum, regardless of specialty or venue.

**Conclusion**

Identifying and bridging performance gaps is central to health care quality. COPD represents an important target condition in which to implement measures to improve care.
Authors contributions

CK: data collection and analysis, manuscript writing critical revision and final approval of the manuscript.
SM: conception and design, critical revision and final approval of the manuscript.
SH: data analysis, critical revision and final approval of the manuscript.
KD: conception, critical revision and final approval of the manuscript
OS: statistics and analysis, critical revision and final approval of the manuscript
TR: conception and design, financial support, critical revision and final approval of the manuscript.
CS: conception and design, financial support, data collection and analysis, manuscript writing and final approval of the manuscript.
All authors read and approved the final manuscript.

Acknowledgements
We are grateful to all the participating practice teams. Niklaus Brändli, Oskar Denzler, Markus Frey, Walter Schweizer, Alfred Staehelin-Wey, Praxisgemeinschaft Bruno Maggi, Daniel Oertle-Meyer, Praxisgemeinschaft Affoltern (Beat Coradi, Martin Schütz), Praxisgemeinschaft Altstetten (René Christen, Sergio Dallafior, Peter Simic, Adrian Glarner), Medix-Gruppenpraxis (Felix Huber, Claudia Steurer-Stey) Gemeinschaftspraxis am Meierhofplatz, (Renate Albrecht, Peter Christen, Marco Zoller), Dorfpraxis Ottenbach, (Eveline Breidenstein, Erich Villiger), Gruppenpraxis Schlossberg (Urs Aemissegger, Akiko Krähenmann, Fiona Fröhlich, Regula Rutz). Sanacare Gruppenpraxis in Winterthur and Zurich Wiedikon.

A special thank belongs to the Department of Health of the Canton of Zurich for the support and funding of this project.

We also like to thank Sibylle Kohler, MD for revision of the English as a native speaker.
References


Figure 1: legend

Comparison of documented COPD performance measures between primary care practices without a COPD program and the practice running the “Living well with COPD” program
Table 1: Characteristics of the participating practices

<table>
<thead>
<tr>
<th>Practices characteristics by regions</th>
<th>Total (n=14)</th>
<th>Total – practice with COPD program (B) (n=13)</th>
<th>Winterthur (n=5)</th>
<th>Zurich – B (n=8)</th>
<th>Zurich practice with COPD program (B) (n=1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients in single practices, n (%)</td>
<td>20 (17)</td>
<td>20 (21)</td>
<td>10 (27)</td>
<td>10 (17)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>No. of patients in group practices, n (%)</td>
<td>95 (83)</td>
<td>75 (79)</td>
<td>27 (73)</td>
<td>48 (83)</td>
<td>20 (100)</td>
</tr>
<tr>
<td>Total No. of patients, n (%)</td>
<td>115(100)</td>
<td>95 (83)</td>
<td>37 (32)</td>
<td>58 (50)</td>
<td>20 (17)</td>
</tr>
<tr>
<td>No. of computer based medical records, n (%)</td>
<td>91 (79)</td>
<td>71 (75)</td>
<td>31 (84)</td>
<td>40 (69)</td>
<td>20 (100)</td>
</tr>
<tr>
<td>No. of paper based medical records, n (%)</td>
<td>24 (21)</td>
<td>24 (25)</td>
<td>6 (16)</td>
<td>18 (31)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Patient characteristics</td>
<td>Total (n=115)</td>
<td>Total – B (n=95)</td>
<td>Winterthur (n=37)</td>
<td>Zurich – B (n=58)</td>
<td>B (n=20)</td>
</tr>
<tr>
<td>-------------------------</td>
<td>---------------</td>
<td>------------------</td>
<td>------------------</td>
<td>--------------------</td>
<td>---------</td>
</tr>
<tr>
<td><strong>Age, years, mean (range: Min 44y, Max 93 y)</strong></td>
<td>68.25</td>
<td>68.74</td>
<td>64.25</td>
<td>72.25</td>
<td>68.70</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>66 (57)</td>
<td>58 (61)</td>
<td>21 (57)</td>
<td>37 (64)</td>
<td>8 (40)</td>
</tr>
<tr>
<td>BMI (kg/m2), (range: Min 17kg/m2, Max 43kg/m2)</td>
<td>27</td>
<td>27</td>
<td>27</td>
<td>27</td>
<td>26</td>
</tr>
<tr>
<td>Current smokers, n (%)</td>
<td>50 (46)</td>
<td>37 (41)</td>
<td>17 (52)</td>
<td>20 (35)</td>
<td>13 (68)*</td>
</tr>
<tr>
<td>Pack Years, mean (range: 22-150 years)</td>
<td>56</td>
<td>57</td>
<td>50</td>
<td>62</td>
<td>47</td>
</tr>
<tr>
<td>≥ 1 Comorbidities*, n (%)</td>
<td>84 (73)</td>
<td>73 (76)</td>
<td>28 (76)</td>
<td>45 (78)</td>
<td>11 (55)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>17 (15)</td>
<td>17 (18)</td>
<td>6 (16)</td>
<td>11 (19)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>65 (57)</td>
<td>57 (60)</td>
<td>21 (57)</td>
<td>36 (62)</td>
<td>8 (40)</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>32 (28)</td>
<td>28 (29)</td>
<td>7 (19)</td>
<td>21 (36)</td>
<td>4 (20)</td>
</tr>
<tr>
<td>Heart failure</td>
<td>10 (9)</td>
<td>10 (11)</td>
<td>3 (8)</td>
<td>7 (12)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Depression</td>
<td>27 (23)</td>
<td>23 (24)</td>
<td>10 (27)</td>
<td>13 (22)</td>
<td>4 (20)</td>
</tr>
<tr>
<td>Spirometry at COPD onset, n (%)</td>
<td>72 (59)</td>
<td>61 (57)</td>
<td>23 (62)</td>
<td>38 (66)</td>
<td>11 (63)</td>
</tr>
<tr>
<td>GOLD at COPD onset, n (%)</td>
<td>80 (70)</td>
<td>68 (72)</td>
<td>24 (65)</td>
<td>44 (76)</td>
<td>12 (60)</td>
</tr>
<tr>
<td>GOLD I at COPD onset, n (%)</td>
<td>9 (11)</td>
<td>9 (13)</td>
<td>3 (13)</td>
<td>6 (14)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>GOLD II at COPD onset, n (%)</td>
<td>51 (64)</td>
<td>41 (60)</td>
<td>14 (58)</td>
<td>27 (61)</td>
<td>10 (83)</td>
</tr>
<tr>
<td>GOLD III at COPD onset, n (%)</td>
<td>17 (21)</td>
<td>16 (24)</td>
<td>7 (29)</td>
<td>9 (20)</td>
<td>1 (8)</td>
</tr>
<tr>
<td>GOLD IV at COPD onset, n (%)</td>
<td>3 (4)</td>
<td>2 (3)</td>
<td>0 (0)</td>
<td>2 (5)</td>
<td>1 (5)</td>
</tr>
<tr>
<td>Spirometry in 2012, n (%)</td>
<td>67 (58)</td>
<td>48 (51)</td>
<td>19 (51)</td>
<td>29 (50)</td>
<td>19 (95)**</td>
</tr>
<tr>
<td>GOLD in 2012, n (%)</td>
<td>87 (76)</td>
<td>68 (72)</td>
<td>24 (65)</td>
<td>44 (76)</td>
<td>19 (95)</td>
</tr>
<tr>
<td>GOLD I in 2012, n (%)</td>
<td>7 (8)</td>
<td>6 (9)</td>
<td>3 (13)</td>
<td>3 (7)</td>
<td>1 (5)</td>
</tr>
<tr>
<td>GOLD II in 2012, n (%)</td>
<td>44 (51)</td>
<td>34 (50)</td>
<td>12 (50)</td>
<td>22 (50)</td>
<td>10 (53)</td>
</tr>
<tr>
<td>GOLD III in 2012, n (%)</td>
<td>28 (23)</td>
<td>23 (34)</td>
<td>9 (38)</td>
<td>14 (32)</td>
<td>5 (26)</td>
</tr>
<tr>
<td>GOLD IV in 2012, n (%)</td>
<td>8 (9)</td>
<td>5 (7)</td>
<td>0 (0)</td>
<td>5 (11)</td>
<td>3 (16)</td>
</tr>
<tr>
<td>Years since COPD onset, mean range (Min 1y, Max 16y)</td>
<td>5.28</td>
<td>5.69</td>
<td>4.32</td>
<td>6.54#</td>
<td>2.69**</td>
</tr>
<tr>
<td>Cough, n (%)</td>
<td>62 (54)</td>
<td>54 (57)</td>
<td>18 (49)</td>
<td>36 (62)</td>
<td>8 (40)</td>
</tr>
<tr>
<td>Sputum production, n (%)</td>
<td>40 (35)</td>
<td>32 (34)</td>
<td>9 (24)</td>
<td>23 (40)</td>
<td>8 (40)</td>
</tr>
<tr>
<td>Dyspnoe, n (%)</td>
<td>78 (68)</td>
<td>62 (65)</td>
<td>22 (59)</td>
<td>40 (70)</td>
<td>16 (80)</td>
</tr>
<tr>
<td>Severity of dyspnea (MRC scale): 0-2, n (%)</td>
<td>22 (76)</td>
<td>8 (67)</td>
<td>3 (75)</td>
<td>5 (63)</td>
<td>14 (82)</td>
</tr>
<tr>
<td>Severity of dyspnea (MRC scale): &gt;2, n (%)</td>
<td>7 (24)</td>
<td>4 (33)</td>
<td>1 (25)</td>
<td>3 (38)</td>
<td>3 (15)</td>
</tr>
<tr>
<td>Exacerbations/year, mean (range: 0-4 Exacerbations)</td>
<td>1.39</td>
<td>1.42</td>
<td>1.28</td>
<td>1.50</td>
<td>1.27</td>
</tr>
<tr>
<td>≥2 Exacerbations/year, n (%)</td>
<td>16 (16)</td>
<td>13 (26)</td>
<td>4 (22)</td>
<td>9 (28)</td>
<td>3 (27)</td>
</tr>
<tr>
<td>Hospitalisations/year, mean (range: 0-3 Hospitalisations)</td>
<td>1.24</td>
<td>1.25</td>
<td>1.00</td>
<td>1.33</td>
<td>1.20</td>
</tr>
</tbody>
</table>
*p=0.030; **p<0.01 compared to (Total-B); #p=0.012 compared to Winterthur

*The comorbidities heart failure and diabetes were not documented in the twenty patients from practice B, therefore statistical comparison can’t be done between B and the other practices.
Table 3: Documentation of non-pharmacological measures (% depend on the amount (n) of documented characteristics)

<table>
<thead>
<tr>
<th>Documentation of performance measures</th>
<th>Total (n=115)</th>
<th>Total – B (n=95)</th>
<th>Winterthur (n=37)</th>
<th>Zurich – B (n=58)</th>
<th>B (n=20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Assessment of smoking status, n (%)</td>
<td>109 (95)</td>
<td>90 (95)</td>
<td>33 (89)</td>
<td>57 (98)</td>
<td>19 (95)</td>
</tr>
<tr>
<td>Smoking cessation advice, n (%)</td>
<td>37 (74)</td>
<td>24 (65)</td>
<td>12 (71)</td>
<td>12 (60)</td>
<td>13</td>
</tr>
<tr>
<td>(n=50 active smokers)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(100)*</td>
</tr>
<tr>
<td>Smoking cessation intervention, n (%) (n=50 active smokers)</td>
<td>26 (52)</td>
<td>14 (38)</td>
<td>9 (53)</td>
<td>5 (25)</td>
<td>12 (92) **</td>
</tr>
<tr>
<td>Annual influenza vaccination, n (%)</td>
<td>56 (49)</td>
<td>47 (49)</td>
<td>16 (43)</td>
<td>31 (53)</td>
<td>9 (45)</td>
</tr>
<tr>
<td>Assessment of physical activity, n (%)</td>
<td>69 (60)</td>
<td>50 (52)</td>
<td>20 (54)</td>
<td>30 (52)</td>
<td>19 (95) **</td>
</tr>
<tr>
<td>Advice for physical activity, n (%)</td>
<td>61 (53)</td>
<td>42 (44)</td>
<td>17 (46)</td>
<td>25 (43)</td>
<td>19 (95) **</td>
</tr>
<tr>
<td>Instruction in correct inhalation technique, n (%)</td>
<td>65 (57)</td>
<td>46 (48)</td>
<td>13 (35)</td>
<td>33 (57)#</td>
<td>19 (95) **</td>
</tr>
<tr>
<td>Information about the therapy, n (%)</td>
<td>62 (54)</td>
<td>43 (45)</td>
<td>12 (32)</td>
<td>31 (53)#</td>
<td>19 (95) **</td>
</tr>
<tr>
<td>Information about disease, n (%)</td>
<td>64 (56)</td>
<td>45 (47)</td>
<td>15 (41)</td>
<td>30 (51)</td>
<td>19 (95) **</td>
</tr>
<tr>
<td>Instruction in exacerbation management with a written action plan, n (%)</td>
<td>28 (24)</td>
<td>8 (8)</td>
<td>3 (8)</td>
<td>5 (9)</td>
<td>20 (100) **</td>
</tr>
<tr>
<td>Use of a written action plan, n (%)</td>
<td>18 (16)</td>
<td>2 (2)</td>
<td>1 (3)</td>
<td>1 (2)</td>
<td>16 (80) **</td>
</tr>
<tr>
<td>Advice of pulmonary rehabilitation, n (%)</td>
<td>31 (27)</td>
<td>11 (12)</td>
<td>4 (11)</td>
<td>7 (12)</td>
<td>20 (100) **</td>
</tr>
<tr>
<td>Referral to a pulmonary rehabilitation, n (%)</td>
<td>28 (24)</td>
<td>11 (12)</td>
<td>5 (14)</td>
<td>6 (10)</td>
<td>17 (85) **</td>
</tr>
<tr>
<td>Integrated and coordinated care, n (%)</td>
<td>69 (60)</td>
<td>50 (53)</td>
<td>16 (43)</td>
<td>34 (59)</td>
<td>19 (95) **</td>
</tr>
<tr>
<td>Proactive care, n (%)</td>
<td>59 (51)</td>
<td>40 (42)</td>
<td>12 (32)</td>
<td>28 (48)</td>
<td>19 (95) **</td>
</tr>
</tbody>
</table>

*p=0.012; **p<0.01 compared to Total-B; #p<0.05 compared to Winterthur
Table 4: Pharmalogical treatment (% depend on the amount (n) of documented characteristics)

<table>
<thead>
<tr>
<th>Drug</th>
<th>Total (n = 115)</th>
<th>Total – B (n = 95)</th>
<th>Winterthur (n = 37)</th>
<th>Zurich – B (n = 58)</th>
<th>B (n = 20)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICS/LABA, n (%)</td>
<td>70 (61)</td>
<td>56 (59)</td>
<td>16 (43)</td>
<td>40 (69)*</td>
<td>14 (70)</td>
</tr>
<tr>
<td>ICS, n (%)</td>
<td>10 (9)</td>
<td>9 (9)</td>
<td>4 (11)</td>
<td>5 (9)</td>
<td>1 (5)</td>
</tr>
<tr>
<td>LAMA, n (%)</td>
<td>81 (70)</td>
<td>65 (68)</td>
<td>31 (84)</td>
<td>34 (59)**</td>
<td>16 (80)</td>
</tr>
<tr>
<td>LABA, n (%)</td>
<td>25 (22)</td>
<td>21 (22)</td>
<td>12 (32)</td>
<td>9 (16)</td>
<td>4 (20)</td>
</tr>
<tr>
<td>SABA, n (%)</td>
<td>41 (36)</td>
<td>31 (33)</td>
<td>16 (43)</td>
<td>15 (26)</td>
<td>10 (50)</td>
</tr>
<tr>
<td>SABA/SAMA, n (%)</td>
<td>6 (5)</td>
<td>6 (6)</td>
<td>0 (0)</td>
<td>6 (10)</td>
<td>0 (0)</td>
</tr>
</tbody>
</table>

*p=0.013; **p=0.010 compared to Winterthur

Abbreviations:
LABA = Long-acting beta2-agonist; ICS = Inhaled corticosteroids
ICS/LABA = Combination of a long-acting beta2-agonist and an inhaled corticosteroid in a single inhaler; LAMA = Long-acting antimuscarine antagonist; SABA = Short-acting beta2-agonist
SAMA = Short-acting antimuscarine antagonist; SABA/SAMA = Combination of a short-acting beta2-agonist and a short-acting antimuscarine antagonist in a single inhaler